This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Ophthalmol. 2000;118:1132-1133.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Brimonidine tartrate is an -agonist that currently is used to treat glaucoma by decreasing aqueous production and by possibly increasing uveal scleral outflow. It is a lipid-soluble agent that can cross the blood-brain barrier and can have, in theory, some psychoactive properties. It has been reported that dizziness and depression could occur owing to the aforementioned properties.¹ I report a case involving acute psychosis and delirium in a patient receiving brimonidine (Alphagan; Allergan Inc, Irvine, Calif), which resolved immediately after cessation of the agent.

Report of a Case

A 68-year-old man with mild open-angle glaucoma received brimonidine after -blockers failed to lower his intraocular pressure. The patient received brimonidine for about 3 months before the family began to notice dramatic behavioral changes. In retrospect, the patient's wife reported that he began having subtle lapses in memory almost on initiation of treatment. Following this, the patient started complaining of being constantly tired and began exhibiting . . . [Full Text of this Article]

Comment
David D. Kim, MD
Green Bay, Wis

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Charles Bonnet syndrome and brimonidine: comments
Rahman et al.
Br J Ophthalmol 2004;88:724-724.
FULL TEXT  

Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops
Tomsak et al.
Br J Ophthalmol 2003;87:917-917.
FULL TEXT